Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A multicentre open-label RCT testing whether 12-month mHealth home telemonitoring improves blood pressure and HbA1c versus standard care in older adults with hypertension and type 2 diabetes. PICO summary and expert commentary.
An open-label randomized trial in newly diagnosed type 2 diabetes found acarbose and vildagliptin both lowered plasma TMAO, with a greater fall on acarbose. PICO summary and expert commentary.
A 92-patient randomized trial in Taiwan tested whether 6-month health coaching improves eGFR in type 2 diabetes with early-stage CKD. PICO summary and expert commentary.
An exploratory plasma proteomic analysis of the Phase 2b MOSAIC trial maps selonsertib activity to fibrosis, inflammation and oxidative-stress pathways in diabetic kidney disease, with PICO summary and expert commentary.
A prespecified FIGARO-DKD subgroup analysis of 325 Chinese adults with type 2 diabetes and CKD found a significant reduction in the secondary kidney outcome with finerenone but no significant cardiovascular benefit. PICO summary and expert commentary.
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.